Rajesh Devraj, Rectify Pharmaceuticals CEO

At­las backs a long­time Ver­tex em­ploy­ee’s quest to bring CF suc­cess to nu­mer­ous oth­er dis­eases

One of Ver­tex’s longest-tenured em­ploy­ees be­lieves he can take the biotech’s biggest med­ical and sci­en­tif­ic ac­com­plish­ments and use it to de­vel­op treat­ments for more than just cys­tic fi­bro­sis.

Three years ago, Jonathan Moore, a sci­en­tist and then ex­ec­u­tive at Ver­tex from 1990 to 2018, found­ed a com­pa­ny to de­vel­op treat­ments for dis­eases that, like CF, are caused by mu­ta­tions in a “su­per fam­i­ly” of pro­teins known as ABC trans­porters.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.